Send to printer »

GEN News Highlights : Jul 15, 2009

BioWa Grants Merck KGaA Access to Technology that Enhances Antibody-Dependent Cellular Cytotoxicity

Merck KGaA licensed access to BioWa's Potelligent® Technology for the research, development, and commercialization of its antibody therapies. Under this nonexclusive agreement, BioWa received up-front fees and may earn development milestone payments and royalties.

Potelligent is designed to improve potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.